Rakeen Mabud on Greedflation, Rachel K. Jones on Mifepristone

['.Wp-Block-Co-Authors-Plus-Coauthors.Is-Layout-Flow', 'Class', 'Wp-Block-Co-Authors-Plus', 'Display Inline', '.Wp-Block-Co-Authors-Plus-Avatar', 'Where Img', 'Height Auto Max-Width', 'Vertical-Align Bottom .Wp-Block-Co-Authors-Plus-Coauthors.Is-Layout-Flow .Wp-Block-Co-Authors-Plus-Avatar', 'Vertical-Align Middle .Wp-Block-Co-Authors-Plus-Avatar Is .Alignleft .Alignright', 'Display Table .Wp-Block-Co-Authors-Plus-Avatar.Aligncenter Display Table Margin-Inline Auto'] CounterSpin 2024-04-05 14:58:04

This week on CounterSpin: In the final quarter of 2023, after-tax corporate profits reached an all-time high of $2.8 trillion. As one economist put it, “If people are paying $3 for a dozen eggs last week, they’ll pay $3 this week. And firms take advantage of that.” One reason we have details on “greedflation” is the work of the Groundwork Collaborative. We spoke with their economist and managing director of policy and research, Rakeen Mabud, a few months back. The Washington Post has described it as a “confusing legal battle,” but CounterSpin got clarity from the Guttmacher Institute’s Rachel K. Jones last year.